<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471298</url>
  </required_header>
  <id_info>
    <org_study_id>TSL-TCM-QSYQDW-I</org_study_id>
    <nct_id>NCT04471298</nct_id>
  </id_info>
  <brief_title>A Study of Qishenyiqi Dripping Pills in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Evaluate the Safety and Tolerability of Continuous Oral Treatment With Qishenyiqi Dripping Pills in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceutical Group Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy&#xD;
      participants, following oral administration with multiple escalating dose of it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Qishenyiqi dripping pills, which are made of Huangqi, Danshen, Sanqi, active ingredients of&#xD;
      Jiangxiang, have the efficacy of beneficial effects of qi and pulse, blood circulation and&#xD;
      pain relief.&#xD;
&#xD;
      This study is a randomized, double-blind, placebo-controlled, dose-escalation design study,&#xD;
      including three cohorts and 36 healthy participants. Within each cohort, participant will&#xD;
      receive Qishenyiqi dripping pills at the selected dose level by oral administration three&#xD;
      times a day for 28 consecutive days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Actual">January 11, 2021</completion_date>
  <primary_completion_date type="Actual">January 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From screening (2 weeks in advance) till follow-up visit (up to 1week)</time_frame>
    <description>Observe all the adverse events of all participants administrated orally with Qishenyiqi dripping pills.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal vital signs index (body temperature)</measure>
    <time_frame>From screening (2 weeks in advance) till the end of trial period (Day 29)</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal vital signs index (pulse rate)</measure>
    <time_frame>From screening (2 weeks in advance) till the end of trial period (Day 29)</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal vital signs index (respiratory rate)</measure>
    <time_frame>From screening (2 weeks in advance) till the end of trial period (Day 29)</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal vital signs index (blood pressure)</measure>
    <time_frame>From screening (2 weeks in advance) till the end of trial period (Day 29)</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>The complete physical examinations will include an assessment of the general appearance, skin, cardiovascular, abdomen, head, and neck, lymph nodes, musculoskeletal and neurological systems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory assessments (blood routine test)</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory assessments (blood biochemical test)</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory assessments (coagulation function test)</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory assessments (urinalysis routine test)</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory assessments (fecal routine test)</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)</measure>
    <time_frame>screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Active dosage group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Qishenyiqi dripping pills, 3.12g, oral, three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active dosage group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Qishenyiqi dripping pills, 4.68g, oral, three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active dosage group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Qishenyiqi dripping pills, 6.24g, oral, three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control dosage group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control dosage group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control dosage group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi dripping pills, 6 bags</intervention_name>
    <description>28 consecutive days</description>
    <arm_group_label>Active dosage group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi dripping pills, 9 bags</intervention_name>
    <description>28 consecutive days</description>
    <arm_group_label>Active dosage group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi dripping pills, 12 bags</intervention_name>
    <description>28 consecutive days</description>
    <arm_group_label>Active dosage group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi dripping pills placebo, 6 bags</intervention_name>
    <description>28 consecutive days</description>
    <arm_group_label>Control dosage group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi dripping pills placebo, 9 bags</intervention_name>
    <description>28 consecutive days</description>
    <arm_group_label>Control dosage group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi dripping pills placebo, 12 bags</intervention_name>
    <description>28 consecutive days</description>
    <arm_group_label>Control dosage group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers, male or female, aged 18-50 years (including the boundary value);&#xD;
&#xD;
          -  Participants weigh at least 50.0 kg in male and 45.0 kg in female with a body mass&#xD;
             index of all subjects between 19 and 26kg/m2 (including the boundary value);&#xD;
&#xD;
          -  Participants are willing to have no pregnancy program and take effective contraceptive&#xD;
             measures voluntarily since signing informed consent form to 3 months after the last&#xD;
             administration;&#xD;
&#xD;
          -  Participants are willing to sign Independent Ethics Committee (IEC)-approved informed&#xD;
             consent form and able to understand and comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with allergic constitution or have a history of allergy to drug or food;&#xD;
&#xD;
          -  Participants with diseases or physiological conditions that may affect the study,&#xD;
             including but not limited to diseases of the nervous, mental, respiratory,&#xD;
             cardiovascular, digestive, blood and lymphatic, endocrine, musculoskeletal systems,&#xD;
             liver and kidney dysfunction;&#xD;
&#xD;
          -  Participants who have any clinically significant abnormalities in vital signs,&#xD;
             physical examination, electrocardiogram, chest radiograph, abdominal ultrasound and&#xD;
             laboratory examination;&#xD;
&#xD;
          -  Participants who have positive test for hepatitis B virus surface antigen (except&#xD;
             surface antibodies), hepatitis C virus antibody, human immunodeficiency virus antibody&#xD;
             and treponema pallidum antibody;&#xD;
&#xD;
          -  Women who are in the state of pregnancy or lactation;&#xD;
&#xD;
          -  Participants who have a history of drug abuse or a positive test result for drug abuse&#xD;
             at screening;&#xD;
&#xD;
          -  Participants who have smoked more than 5 cigarette per day or used a considerable&#xD;
             amount of nicotine-containing products within the previous 3 months, and could not&#xD;
             quit smoking during the experiment;&#xD;
&#xD;
          -  Participants who have been drinking more than 14 units of alcohol per week within the&#xD;
             previous 3 months (1 unit ≈285 mL beer with 3.5% alcohol or 25 mL spirits with 40%&#xD;
             alcohol or 85 mL wines with 12% alcohol), or positive test for alcohol, or could not&#xD;
             abstain from drinking during the trial;&#xD;
&#xD;
          -  Participants who have taken any prescription drugs (including prescription,&#xD;
             nonprescription, herbal medicine, dietary supplement such as vitamin product and&#xD;
             calcium tablet) within 4 weeks before administration of investigational drugs;&#xD;
&#xD;
          -  Participants who have difficulty in venous blood collection or history of fainting&#xD;
             blood or needles;&#xD;
&#xD;
          -  Participants who have participated in any drug clinical trial within 3 months and have&#xD;
             taken the experimental drug or plan to participate in other clinical trials during the&#xD;
             trial period;&#xD;
&#xD;
          -  Participants who have donated or lost blood ≥200 mL within 3 months or received blood&#xD;
             transfusion or used blood products, or have blood donation plan during the trial&#xD;
             period;&#xD;
&#xD;
          -  Judged by the investigator, participants have poor compliance or have other factors&#xD;
             such as clinical, social or family that should not be included in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Teaching Hospital of Tianjin University of TCM</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 3, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Qishenyiqi Dripping Pills</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

